Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Angela R. Branche; Nadine G. Rouphael; Cecilia Losada; Lindsey R. Baden; Evan J. Anderson; Anne F. Luetkemeyer; David J. Diemert; Patricia L. Winokur; Rachel M. Presti; Angelica C. Kottkamp; Ann R. Falsey; Sharon E. Frey; Richard Rupp; Martín Bäcker; Richard M. Novak; Emmanuel B. Walter; Lisa A. Jackson; Susan J. Little; Lilly C. Immergluck; Siham M. Mahgoub; Jennifer A. Whitaker; Tara M. Babu; Paul A. Goepfert; Dahlene N. Fusco; Robert L. Atmar; Christine M. Posavad; Antonia Netzl; Derek J. Smith; Kalyani Telu; Jinjian Mu; Mat Makowski; Mamodikoe K. Makhene; Sonja Crandon; David C. Montefiori; Paul C. Roberts; John H. Beigel

doi:10.1093/cid/ciad209

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Angela R. Branche, Nadine G. Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David J. Diemert, Patricia L. Winokur, Rachel M. Presti, Angelica C. Kottkamp, Ann R. Falsey, Sharon E. Frey, Richard Rupp, Martín Bäcker, Richard M. Novak, Emmanuel B. Walter, Lisa A. Jackson, Susan J. Little, Lilly C. Immergluck, Siham M. MahgoubJennifer A. Whitaker, Tara M. Babu, Paul A. Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Mat Makowski, Mamodikoe K. Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-Type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

Original language	English (US)
Pages (from-to)	560-564
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	77
Issue number	4
DOIs	https://doi.org/10.1093/cid/ciad209
State	Published - Aug 15 2023
Externally published	Yes

Keywords

SARS-CoV-2
vaccine
variant

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciad209

Cite this

Branche, A. R., Rouphael, N. G., Losada, C., Baden, L. R., Anderson, E. J., Luetkemeyer, A. F., Diemert, D. J., Winokur, P. L., Presti, R. M., Kottkamp, A. C., Falsey, A. R., Frey, S. E., Rupp, R., Bäcker, M., Novak, R. M., Walter, E. B., Jackson, L. A., Little, S. J., Immergluck, L. C., ... Beigel, J. H. (2023). Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial. Clinical Infectious Diseases, 77(4), 560-564. https://doi.org/10.1093/cid/ciad209

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial. / Branche, Angela R.; Rouphael, Nadine G.; Losada, Cecilia et al.
In: Clinical Infectious Diseases, Vol. 77, No. 4, 15.08.2023, p. 560-564.

Research output: Contribution to journal › Article › peer-review

Branche, AR, Rouphael, NG, Losada, C, Baden, LR, Anderson, EJ, Luetkemeyer, AF, Diemert, DJ, Winokur, PL, Presti, RM, Kottkamp, AC, Falsey, AR, Frey, SE, Rupp, R, Bäcker, M, Novak, RM, Walter, EB, Jackson, LA, Little, SJ, Immergluck, LC, Mahgoub, SM, Whitaker, JA, Babu, TM, Goepfert, PA, Fusco, DN, Atmar, RL, Posavad, CM, Netzl, A, Smith, DJ, Telu, K, Mu, J, Makowski, M, Makhene, MK, Crandon, S, Montefiori, DC, Roberts, PC & Beigel, JH 2023, 'Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial', Clinical Infectious Diseases, vol. 77, no. 4, pp. 560-564. https://doi.org/10.1093/cid/ciad209

@article{05d956d396ea4b17a455608aac93f1ea,

title = "Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial",

abstract = "In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-Type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.",

keywords = "SARS-CoV-2, vaccine, variant",

author = "Branche, \{Angela R.\} and Rouphael, \{Nadine G.\} and Cecilia Losada and Baden, \{Lindsey R.\} and Anderson, \{Evan J.\} and Luetkemeyer, \{Anne F.\} and Diemert, \{David J.\} and Winokur, \{Patricia L.\} and Presti, \{Rachel M.\} and Kottkamp, \{Angelica C.\} and Falsey, \{Ann R.\} and Frey, \{Sharon E.\} and Richard Rupp and Mart{\'i}n B{\"a}cker and Novak, \{Richard M.\} and Walter, \{Emmanuel B.\} and Jackson, \{Lisa A.\} and Little, \{Susan J.\} and Immergluck, \{Lilly C.\} and Mahgoub, \{Siham M.\} and Whitaker, \{Jennifer A.\} and Babu, \{Tara M.\} and Goepfert, \{Paul A.\} and Fusco, \{Dahlene N.\} and Atmar, \{Robert L.\} and Posavad, \{Christine M.\} and Antonia Netzl and Smith, \{Derek J.\} and Kalyani Telu and Jinjian Mu and Mat Makowski and Makhene, \{Mamodikoe K.\} and Sonja Crandon and Montefiori, \{David C.\} and Roberts, \{Paul C.\} and Beigel, \{John H.\}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s).",

year = "2023",

month = aug,

day = "15",

doi = "10.1093/cid/ciad209",

language = "English (US)",

volume = "77",

pages = "560--564",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts

T2 - Preliminary Results from the COVAIL Randomized Clinical Trial

AU - Branche, Angela R.

AU - Rouphael, Nadine G.

AU - Losada, Cecilia

AU - Baden, Lindsey R.

AU - Anderson, Evan J.

AU - Luetkemeyer, Anne F.

AU - Diemert, David J.

AU - Winokur, Patricia L.

AU - Presti, Rachel M.

AU - Kottkamp, Angelica C.

AU - Falsey, Ann R.

AU - Frey, Sharon E.

AU - Rupp, Richard

AU - Bäcker, Martín

AU - Novak, Richard M.

AU - Walter, Emmanuel B.

AU - Jackson, Lisa A.

AU - Little, Susan J.

AU - Immergluck, Lilly C.

AU - Mahgoub, Siham M.

AU - Whitaker, Jennifer A.

AU - Babu, Tara M.

AU - Goepfert, Paul A.

AU - Fusco, Dahlene N.

AU - Atmar, Robert L.

AU - Posavad, Christine M.

AU - Netzl, Antonia

AU - Smith, Derek J.

AU - Telu, Kalyani

AU - Mu, Jinjian

AU - Makowski, Mat

AU - Makhene, Mamodikoe K.

AU - Crandon, Sonja

AU - Montefiori, David C.

AU - Roberts, Paul C.

AU - Beigel, John H.

PY - 2023/8/15

Y1 - 2023/8/15

N2 - In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-Type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

AB - In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-Type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.

KW - SARS-CoV-2

KW - vaccine

KW - variant

UR - http://www.scopus.com/inward/record.url?scp=85164227884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164227884&partnerID=8YFLogxK

U2 - 10.1093/cid/ciad209

DO - 10.1093/cid/ciad209

M3 - Article

C2 - 37036397

AN - SCOPUS:85164227884

SN - 1058-4838

VL - 77

SP - 560

EP - 564

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 4

ER -

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this